期刊文献+

α酮酸联合低分子肝素钠对血透患者钙磷代谢影响的观察 被引量:6

下载PDF
导出
摘要 钙磷代谢紊乱是维持性血液透析患者面临的常见问题,由其导致的肾眭骨病、继发性甲状旁腺功能亢进和心血管并发症与患者的生存率和死亡率息息相关,故纠正钙磷代谢紊乱是优化肾脏替代治疗的重要组成部分。目前控制低钙高磷血症的方法主要有限制饮食含磷量和使用肠道磷结合剂、钙剂,但作用均有限;因此,如何在血液透析过程中,有效的预防和控制低钙高磷血症已成为关注的焦点,因此,本文通过对比普通肝素钠组观察了α酮酸联合低分子肝素钠组对维持性血液透析患者纠正钙磷代谢紊乱的作用,现报告如下。
出处 《中国中西医结合肾病杂志》 2012年第12期1108-1109,共2页 Chinese Journal of Integrated Traditional and Western Nephrology
  • 相关文献

参考文献6

二级参考文献45

  • 1孙鲁英,王梅,杨莉.终末期肾脏病患者钙磷代谢及甲状旁腺激素水平的临床分析[J].北京大学学报(医学版),2005,37(2):147-150. 被引量:63
  • 2Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis[J].J Am Soc Nephrol, 2004, 15:2208-2218. 被引量:1
  • 3Itoh N, Ornitz DM. Evolution of the FGF and FGFR gene families[J]. Trends Genet, 2004, 20:563-569. 被引量:1
  • 4Yan X, Yokote H, Jing Let al. Fibroblast growth factor 23 reduces expression of type-IIa Na+/Pi co-transporter by signaling through a receptor function ally distinct from the known FGFRs in opossum kidney cells[J]. Genes Cells, 2005,10:489-502. 被引量:1
  • 5Kazama JJ, Gejyo F, Shigematsu T, et al. Role of circulating fihroblast growth factor 23 in the development of secondary hyperparathyroidism[J]. Ther Apher Dial, 2005, 9:328-330. 被引量:1
  • 6Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease[J].J Am Soc Nephrol, 2004,16: 520-528. 被引量:1
  • 7Forley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of calcium and phosphate metabolism in chronic renal disease [J].Am J Kidney Dis, 1998,32: S112-S119. 被引量:1
  • 8Lindsay RM, Alhejaili F, Nesrallah G, et al. Calcium and phosphate balance with quotidian hemodialysis[J].AmJ Kidney Dis, 2003,42 (Suppl 1): 24-29. 被引量:1
  • 9Hutchison, Alastair J. Improving phosphate-binder therapy, a way forward[J]. Nephrol dial Transplant, 2004,19(Suppl 1): 19-24. 被引量:1
  • 10Bellasi A, Kooienga L, Block GA. Phosphate binders: New products and challenges[J]. Bemodial Intern, 2006, 32: S112- S119. 被引量:1

共引文献66

同被引文献51

  • 1孙鲁英,王梅,杨莉.终末期肾脏病患者钙磷代谢及甲状旁腺激素水平的临床分析[J].北京大学学报(医学版),2005,37(2):147-150. 被引量:63
  • 2Rennick A, Kalakeche R, Seel L, et al. Nicotinic acid and nicotin-amide: a review of their use for hyperphosphatemia in dialysis pa-tients [J]. Pharmacotherapy, 2013,33(6): 683-690. 被引量:1
  • 3Di Iorio BR, Bellizzi V, Bellasi A, et al. Phosphate attenuates the an-ti-proteinuric effect of very low-protein diet in CKD patients [J].Nephrol Dial Transplant, 2013,28(3): 632-640. 被引量:1
  • 4Iijima K. Hyperphosphatemia and cardiovascular diseases: impactof vascular calcification and endothelial dysfimction [J]. Clin Calci-um, 2012, 22(10): 1505-1513. 被引量:1
  • 5Kalantar-Zadeh K. Patient education for phosphorus management inchronic kidney disease [J]. Patient Prefer Adherence, 2013, 7:379-390. 被引量:1
  • 6Gameata L, Mircescu G. Effect of low-protein diet supplementedwith keto acids on progression of chronic kidney disease [J]. J RenNutrm, 2013,23(3): 210-213. 被引量:1
  • 7Liu L, Hossain GS, Shin HD, et al. One-step production of a-keto-glutaric acid from glutamic acid with an engineered L-amino aciddeaminase from Proteus mirabilis [J]. J Biotechnol, 2013, 164(1):97-104. 被引量:1
  • 8Lynch KJE, Lynch R, Curhan GC, et al. Prescribed dietary phosphaterestriction and survival among hemodialysis patients [J]. Clin J AmSoc Nephrol, 2011,6(3): 620-629. 被引量:1
  • 9Ho LC,Wang HH,Chiang CK,et al.Malnutrition-inflammation score independently determined cardiovascular and infection risk in peritoneal dialysis patients[J].Blood Purif,2010,30 (1):16-24. 被引量:1
  • 10Wellen KE,Hotamisligil GS.Imflammation,stress,and diabetes[J].J Clin Invest,2005,115(5):1111-1119. 被引量:1

引证文献6

二级引证文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部